J9064 HCPCS Level II code: Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg

J9064 is the HCPCS code for “Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J9064

Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg

Short description: Inj, cabazitaxel (sandoz)

HCPCS · United States

Medicare details

The indicators CMS publishes with J9064 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Carrier judgment
Medicare pricing
Drugs
Type of service
Medical care
BETOS category
Chemotherapy
Added
Oct 1, 2023

Where J9064 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J9064Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J9064 mean?

J9064 is the HCPCS code for “Injection, cabazitaxel (sandoz), not therapeutically equivalent to j9043, 1 mg” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J9064?

CMS lists J9064’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.